Approach to chronic obstructive pulmonary disease in primary care

Canadian Family Physician

Volumn 54, Issue 5, 2008, Pages 706-711

  Todd, David C ^a   McIvor, R Andrew ^a,b   Pugsley, Stewart O ^a   Cox, Gerard ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; OXYGEN; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; VARENICLINE; VITAMIN D;

ANXIETY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COR PULMONALE; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EVIDENCE BASED MEDICINE; HUMAN; HYPERCAPNIA; INFLUENZA; INFLUENZA VACCINATION; MONOTHERAPY; MORBIDITY; OSTEOPENIA; OSTEOPOROSIS; OXYGEN THERAPY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SMOKING; SMOKING CESSATION; SPIROMETRY; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; CASE REPORT; CLASSIFICATION; FEMALE; MIDDLE AGED; PRIMARY HEALTH CARE;

ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; DYSPNEA; FEMALE; HUMANS; MIDDLE AGED; OXYGEN INHALATION THERAPY; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 44449097209     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. O'Donnell DE, Aaron S, Bourbeau J, Bourbeau J, Hernandez P, Marciniuk DD, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14(Suppl B):5B-32B
2. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976-80.
3. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999;159(4 Pt 2):S1-40.
4. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patients with COPD. Relationships to functional capacity. Chest 1985;87:35-8.
5. Incalzi RA, Caradonna P, Ranieri P, Basso S, Fuso L, Pagano F, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000;94:1079-84.
6. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
7. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. Chest 1999;116:306-13.
8. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J 2007;16:41-8.
9. Buffels J, Degryse J, Heyman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO study. Chest 2004;125:1394-9.
10. Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study [abstract]. BMJ 2002;324:1370.
11. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Disease (BOLD) study. Chest 2007;131:29-36.
12. Krahn M, Chapman KR. Economic issues in the use of office spirometry for lung health assessment. Can Respir J 2003;10:320-6.
13. Fink G, Moshe S, Goshen J, Klainman E, Lebzelter J, Spitzer S, et al. Functional evaluation in patients with chronic obstructive pulmonary disease: pulmonary function test versus cardiopulmonary exercise test. J Occup Environ Med 2002;44:54-8.
14. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434-40.
15. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257-66.
16. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167:544-9.
17. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Menez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
18. Imfeld S, Block KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006;129:873-8.
19. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005;26:630-6.
20. Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005;128:3810-6.
21. CG Cote, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.
22. Taylor MC, Dingle JL. Prevention of tobacco-caused disease. In: Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa, ON: Health Canada; 1994. p. 500-11.
23. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
24. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38.
25. Troosters T, Gosselink R, Decramer M. Exercise training in COPD: how to distinguish responders from nonresponders. J Cardiopulm Rehabil 2001;21:10-7.
26. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003;163:585-91.
27. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
28. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korkucki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-26.
29. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
30. Sin DD, Man SF. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr Opin Pulm Med 2007;13:90-7.
31. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
32. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
33. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964-71.
34. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906-13.
35. Bach PB, Brown C, Gelfand S, McCrory D. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001;134:600-20.
36. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
37. Aaron SD, Vendemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-25.
38. McIvor A, Little P. Chronic obstructive pulmonary disease. BMJ 2007;334:798.